The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis
The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis
复制标题
肿瘤坏死因子受体超家族成员 1B 多态性预测自身免疫性疾病患者对抗 TNF 治疗的反应：一项荟萃分析
DOI：
10.1016/j.intimp.2015.05.049
复制
发表时间：
2015-09-01
影响因子：
5.6
通讯作者：
Shi, Yuling
中科院分区：
文献类型：
--
作者：
Chen, Wenjuan;Xu, Hui;Shi, Yuling
关于肿瘤坏死因子受体超家族成员1B （TNFRSF1B）基因多态性的大量已发表数据显示，在类风湿性关节炎（RA）、牛皮癣和克罗恩病（CD）等自身免疫性疾病中，抗tnf治疗的反应或无反应与肿瘤坏死因子受体超家族成员1B （TNFRSF1B）基因多态性相关。本研究的目的是探讨TNFRSF1B rs1061622 T/G或TNFRSF1A A/G rs767455多态性是否可以预测自身免疫性疾病患者对基于抗tnf的治疗的反应。我们对自身免疫性疾病中TNFRSF1B rs1061622 T/G多态性或TNFRSF1A a /G rs767455多态性与抗tnf治疗无反应性之间的关系进行了荟萃分析。最终纳入8项研究，涉及TNFRSF1B rs1061622的929名受试者和TNFRSF1A rs767455的564名受试者。这些研究包括7项关于TNFRSF1B多态性的研究和4项关于TNFRSF1A多态性的研究。meta分析显示，TNFRSF1B rs1061622等位基因与抗tnf治疗无应答者之间存在显著相关性[T/G比值比（OR） 0.72,95%可信区间（CI） 0.57-0.93, p = 0.01]。按疾病类型分层显示TNFRSF1B rs1061622等位基因与RA对TNF拮抗剂无反应之间存在关联(T/G OR 0.69,95% CI 0.48-0.99,p
Numerous published data on the tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) gene polymorphisms are shown to be associated with response or non-response to anti-TNF therapy in autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's Disease (CD). The aim of this study is to investigate whether the TNFRSF1B rs1061622 T/G or TNFRSF1A A/G rs767455 polymorphisms can predict the response to anti-TNF-based therapy in patients with autoimmune diseases. We conducted a meta-analysis of studies on the association between TNFRSF1B rs1061622 T/G polymorphism or TNFRSF1A A/G rs767455 polymorphism and non-responsiveness to anti-TNF therapy in autoimmune diseases. A total of 8 studies involving 929 subjects for TNFRSF1B rs1061622 and 564 subjects for TNFRSF1A rs767455 were finally considered. These studies consisted of seven studies on the TNFRSF1B polymorphism and four studies on the TNFRSF1A polymorphism. Meta-analysis showed significant association between the TNFRSF1B rs1061622 allele and non-responders to anti-TNF therapy [T/G odds ratio (OR) 0.72,95% confidence interval (CI) 0.57-0.93, p = 0.01]. Stratification by disease type indicated an association between the TNFRSF1B rs1061622 allele and non-responders to TNF antagonist in RA (T/G OR 0.69,95% CI 0.48-0.99,p